Leerink Partnrs Has Positive Outlook for Alumis Q3 Earnings

Key Points

• Alumis Inc. has had its Q3 2025 earnings per share estimates raised from ($1.38) to ($0.90) by Leerink Partners, reflecting improved expectations for the company.
• The company reported Q2 earnings of ($1.17) per share, missing the consensus estimate of ($1.11), but it achieved revenue of $2.67 million, surpassing analyst expectations of $1.80 million.
• A consensus rating of "Buy" has been established for Alumis, with various analysts adjusting their price targets and ratings amid shifts in institutional investor activity.

Alumis Inc. (NASDAQ:ALMS - Free Report) - Equities research analysts at Leerink Partnrs boosted their Q3 2025 earnings per share estimates for Alumis in a research report issued on Wednesday, August 13th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($0.90) per share for the quarter, up from their prior forecast of ($1.38). The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. Leerink Partnrs also issued estimates for Alumis' Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($4.31) EPS, FY2026 earnings at ($3.11) EPS, FY2027 earnings at ($3.71) EPS, FY2028 earnings at ($2.39) EPS and FY2029 earnings at ($1.14) EPS.

Alumis (NASDAQ:ALMS - Get Free Report) last released its earnings results on Wednesday, August 13th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The company had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.80 million.

Several other research firms have also recently commented on ALMS. Wells Fargo & Company started coverage on Alumis in a research note on Friday, July 25th. They set an "overweight" rating and a $17.00 target price for the company. Guggenheim raised Alumis to a "buy" rating and set a $18.00 price target on the stock in a research note on Tuesday, June 10th. Wall Street Zen raised Alumis from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 16th. Morgan Stanley reduced their price objective on Alumis from $23.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday, August 15th. Finally, HC Wainwright reissued a "buy" rating and issued a $14.00 price objective on shares of Alumis in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $20.17.

Alumis Trading Up 5.2%

NASDAQ ALMS traded up $0.24 during trading hours on Monday, hitting $4.84. 692,407 shares of the company's stock were exchanged, compared to its average volume of 745,538. The stock has a 50-day simple moving average of $3.73 and a 200 day simple moving average of $4.59. Alumis has a 1-year low of $2.76 and a 1-year high of $13.11.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALMS. Foresite Capital Management VI LLC purchased a new position in shares of Alumis during the fourth quarter valued at approximately $33,033,000. Orbimed Advisors LLC purchased a new position in shares of Alumis during the second quarter valued at approximately $5,779,000. Velan Capital Investment Management LP purchased a new position in shares of Alumis during the second quarter valued at approximately $4,863,000. Samsara Biocapital LLC boosted its position in shares of Alumis by 47.0% during the second quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company's stock valued at $14,404,000 after buying an additional 1,534,872 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. purchased a new position in shares of Alumis during the second quarter valued at approximately $4,198,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.